The cell surface transmembrane receptor TM4SF5 has been implicated in hepatocellular carcinoma (HCC) but its candidacy as a therapeutic target has not been evaluated. Building on a finding that immunization with a peptide vaccine targeting human TM4SF5 can exert prophylactic and therapeutic effects in a murine model of HCC, we developed a monoclonal antibody to characterize expression of TM4SF5 in HCC and target its function there as an anticancer strategy. We found that the antibody modulated cell signaling in HCC cells in vitro, reducing cell motility, modulating E-cadherin expression, altering p27 kip1 localization and increasing RhoA activity. Using a mouse xenograft model of human HCC, we documented the in vivo efficacy of the antibody which suppressed tumor growth in either tumor prevention or treatment designs. Our work offers a preclinical proof of concept for TM4SF5 as a promising target for antibody therapeutics to treat HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers and the second or third most frequent cause of cancer-related death worldwide (1, 2) . HCC is also the most common type of liver cancer and is usually associated with prior hepatitis virus infection or liver cirrhosis. The primary treatment for HCC is surgical resection; however, the high frequency of recurrence and poor liver function following the removal of liver tissue are significant obstacles to recovery (3) . Furthermore, HCC is frequently resistant to conventional chemotherapy and radiotherapy (4) . Therefore, understanding the signaling pathways involved in HCC development and developing targeted therapies is likely to be an important strategy for the effective treatment of HCC (3, 5) .
Tetraspanins, also known as transmembrane 4 superfamily (TM4SF) members, mediate signal transduction events that regulate cell differentiation, activation, growth and migration (6, 7) . For example, TM4SF4 regulates endocrine pancreas differentiation and inhibits Rho family of GTPase-activated cell migration and actin organization in a Rho kinase (ROCK)-independent fashion (7) . The diverse activities of tetraspanins seem to be related to their capacity to associate with various molecules, including integrins and other tetraspanins (8, 9) .
Lately, tetraspanins have also gained attention as both suppressors and promoters of metastasis depending on the particular tetraspanins (10) . Therefore, tetraspanins have emerged as diagnostic and prognostic markers, as well as therapeutic targets for preventing tumor progression (10, 11) .
TM4SF5 is highly expressed in colon carcinomas, pancreatic tumors, and HCC (12, 13) . Lee et al. showed that TM4SF5 is involved in HCC development, specifically by inducing morphological elongation, epithelial-mesenchymal transition (EMT), uncontrolled cell 4 proliferation, and angiogenesis (13, 14) . A synthetic inhibitor targeting TM4SF5, 4'-(ptoluenesulfonyl-amido)-4-hydroxychalcone (TSAHC), has been shown to inhibit HCC growth and metastasis in vitro and in vivo (15) . Therefore, TM4SF5 seems to play an important role in HCC formation, and it is a rational molecular target for the clinical development of HCC therapeutics (16) .
In previous studies, we produced a TM4SF5-specific monoclonal antibody by immunizing mice with a peptide corresponding to a B-cell epitope of human TM4SF5
(denoted the hTM4SF5R2-3 peptide); this peptide was coencapsulated with CpG-DNA in a phosphatidyl-β-oleoyl-γ-palmitoyl ethanolamine : cholesterol hemisuccinate (DOPE:CHEMS) liposome complex (called Lipoplex(O)) (17) . We then confirmed that the antibody markedly delayed the growth of the Huh-7 human HCC cell line, which express endogenous TM4SF5 (18) . We also showed that active immunization with the peptide vaccine had prevented the growth of tumors from subsequently transplanted HCC cells and suppressed the growth of tumors in mice bearing mouse HCC-cell derived tumors (18, 19) .
Herein, we analyzed expression of TM4SF5 in human HCC tissue samples using an anti-TM4SF5 monoclonal antibody. We also assessed the anti-invasiveness and anti-migratory properties of the antibody in vitro in HCC cells. Finally, we measured in vivo anti-tumor activity of the antibody against mouse-derived and human-derived HCC tumors in mice and found that passive immunization, by intraperitoneal injection of this monoclonal antibody, inhibits the progression of tumors in these mouse models of HCC. Therefore, we provide direct evidence that anti-TM4SF5 monoclonal antibody can be a potential therapeutics to treat HCC.
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Materials and Methods
Production of the mouse anti-human TM4SF5R2-3 monoclonal antibody
As described previously (17, 20) , BALB/c mice were injected intraperitoneally with the hTM4SF5R2-3 peptide derived from human TM4SF5 ( 138 NRTLWDRCEAPPRV 151 ) and
CpG-DNA coencapsulated in a DOPE:CHEMS complex four times, each at 10-day intervals.
In accordance with the standard hybridoma purification protocols, we screened for hybridoma cells that produced the anti-hTM4SF5R2-3 peptide-specific monoclonal antibody (21) . The anti-TM4SF5 monoclonal antibody (IgG2a) was purified from the ascitic fluid by protein A column chromatography.
Surface plasmon resonance (SPR) analysis
The binding affinity of the anti-hTM4SF5 monoclonal antibody to the human (hTM4SF5R2-3) and mouse TM4SF5R2-3 peptides (mTM4SF5R2-3) was measured using Biacore 3000 at 25°C. Biotinylated peptides were captured on the flow cell surface of a SA sensor chip coated with streptavidin. Injection of a buffer solution containing biotin served as a negative control. Data were evaluated using Biacore Bia evaluation software version 3.0 (Biacore). The data were analyzed using fitting models for the ligand-analyte interaction such as 1:1 (Langmuir) binding, 1:1 binding with drifting baseline, 1:1 binding with mass transfer, and bivalent analyte. Based on the results, 1:1 binding with mass transfer was selected as a best model. The parameters such as association rate (ka), dissociation rate (kd), the equilibrium dissociation constant (binding constant, K D, kd/ka) , and the chi square value were calculated using the software. The sensorgram data were extracted using the software and the graphs were reproduced using Microsoft Excel program to show the binding affinity.
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Tissue microarrays and immunohistochemistry
For the HCC and normal tissue analysis, formalin-fixed, paraffin-embedded AccuMax tissue arrays were purchased from ISUABXIS with the approval of the Institutional Review
Board in Hallym University. The following arrays were used: normal tissues (A103(9)), various human cancer tissues with corresponding normal tissues (A301(VI)) and human liver cancer tissues (A204, A204(II) and A204(III)). The tissue arrays were stained with the antihTM4SF5 monoclonal antibody (10 μg/ml), according to standard procedures. The percentages of cells expressing TM4SF5 were calculated as the number of TM4SF5-positive cells divided by the total number of cells in each tumor type.
Cell culture
The human HCC cell lines, Huh-7 and SNU-739, were obtained from the Korean Cell Line Bank and were maintained in RPMI 1640 medium with 10% fetal bovine serum (FBS).
The cell lines were characterized by the cell bank using DNA fingerprinting analysis, species verification test, mycoplasma contamination test, and viral contamination test. Mouse BNL 1ME A.7R.1 HCC cells (BNL-HCC cells) were obtained from ATCC (ATCC ® TIB-75 ™ ) and maintained in DMEM medium containing 10% FBS. ATCC characterized the cell line with tests for morphology, post-freeze viability, interspecies determination (isoenzyme analysis), mycoplasma contamination, and bacterial and fungal contamination. All cells were cultured at 37°C in an atmosphere containing 5% CO 2 . We made stocks for each cell line at early passages, and cultures were maintained until passage 20 (within 2 months) and then discarded. 
In vitro cell migration and invasion assays
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Trans-well chambers with 8 μm porosity were used for these assays. For migration assays, the lower side of the trans-well chamber membranes was coated with gelatin (10 μg/well).
For invasion assays, the upper and lower sides of the chamber membranes were coated with Matrigel (1.2 mg/ml) (BD Biosciences) and gelatin, respectively. Huh-7 cells and SNU-739 cells were suspended (1.6~3.3 x 10 5 cells/ml) in serum-free medium with mouse IgG2a isotype control (IgG2a control; Bethyl Laboratories) or the anti-TM4SF5 monoclonal antibody (10 μg/ml) and placed on the top of the trans-well chamber. RPMI medium containing 10% FBS was placed in the lower chamber. After incubation for 12 h ~ 72 h, the cells that invaded to the lower surface of the filters were fixed, stained with crystal violet, and counted under a microscope (E-200, Nikon).
In vitro wound-healing assays
For wound-healing assays, 1x10 6 cells (Huh-7 cells or SNU-739 cells) were placed in a 6-well plate, cultured overnight to confluence in medium containing serum, and the monolayer was wounded with a pipette tip. PBS, IgG2a control, or the anti-hTM4SF5 monoclonal antibody (10 μg/ml) was added to the medium for the indicated times. The cells were fixed with 4% paraformaldehyde for 30 min and stained with Giemsa for 30 min. The number of cells that migrated into the wounded area was counted in three wells per experimental treatment and three wounds per well under a microscope (TS100, Nikon).
Confocal microscopy
Cells were cultured on glass cover slips in 12-well plates 18 h prior to treatment with the anti-hTM4SF5 monoclonal antibody (10 μg/ml). After treatment with the antibody for the indicated times, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% 
Hepatocellular carcinoma mouse model
For the xenograft assays, thirty BALB/cAnCrj-nu/nu mice were inoculated subcutaneously in the dorsal right flank with 5x10 6 Huh-7 cells in 50% Matrigel as previously described (22) . When tumors reached 5 mm in diameter, the mice were randomly divided into three treatment groups (eight mice/group): PBS, IgG2a control, and the anti-TM4SF5 monoclonal antibody. The antibodies (25 mg/kg) were injected twice weekly into the intraperitoneal cavity. Tumor diameters were measured using calipers at 4-day intervals, and tumor volumes were calculated using the formula, width 2 × length/2, as described previously (18) . The mice were sacrificed 40 days after Huh-7 cells injection and the tumors were weighed. For the syngeneic transplanted tumor assay, thirty BALB/c mice were inoculated subcutaneously in the dorsal right flank with 5x10 6 BNL-HCC cells containing 50% Matrigel and the effects of injected PBS, normal IgG control, and the anti-TM4SF5 monoclonal antibody were evaluated as described above. Tumor diameters were measured at 7-day intervals, and tumor volumes were calculated. BALB/c mice were sacrificed 10 weeks after antibody injection, and the tumors were weighed. 
Histology and immunohistochemistry
For histopathological examinations, the tumors and organs were removed and fixed in a 4% buffered formalin solution overnight, embedded in paraffin using standard methods, and cut into 5-μm-thick sections. The deparaffinized sections were then stained with hematoxylin and eosin (H&E). To assess the expression of TM4SF5, the deparaffinized sections were stained with the anti-TM4SF5 monoclonal antibody (10 μg/ml), according to standard procedures using Histostain Plus kit. The samples were then counterstained with hematoxylin.
All images were examined using a Nikon Eclipse E-200 microscope (Nikon).
Statistics
Results are expressed as mean + standard deviation. Statistical significance between two samples was evaluated using the Student's t test. A p-value of <0.05 was taken as statistically significant.
Results
Specificity and affinity of the anti-TM4SF5 monoclonal antibody
As previous data had shown that an anti-TM4SF5 monoclonal antibody reacted against mouse TM4SF5, we sought to explore its specificity towards the human protein. In order to do this, we isolated an anti-TM4SF5 monoclonal antibody (clone #2D4-18) through hybridoma technology using spleen cells obtained from mice that had been immunized with a biosensor, Biacore. The mAb reacted with human and mouse TM4SF5R2-3 peptides with a similar equilibrium dissociation constant (Kd) of ~ 2 nM ( Fig. 1A and 1B) . Together, these data show that the anti-TM4SF5 monoclonal antibody used in this study reacts specifically with TM4SF5 with a high affinity.
Expression of TM4SF5 in human tissues from various origin
It has been reported that TM4SF5 mRNA is expressed in colon carcinoma, pancreatic tumors, and HCC, as determined by reverse transcriptase (RT)-PCR and Northern blotting (12) . Here, we investigated the expression of the TM4SF5 protein in various human tissues including human HCC specimens by immunohistochemical staining with the anti-TM4SF5 monoclonal antibody to validate the presence of the target in HCC. Fig. S4 ). In addition to HCC, TM4SF5 expression was also detected in colon cancer and pancreatic cancer tissues, in agreement with the previously published mRNA data (12) (Fig. 1G and 1H ). These results confirm that this monoclonal antibody is useful for Fig. S5 ). Considering a recent report that 45% of human esophageal cancer tissues showed expression of TM4SF5 in >50% of the tumor cells (23) and the fact that the cancer tissue array we used was composed of just one case per each cancer, detailed studies are required to clarify the implication of TM4SF5 in other cancer types.
Effect of the anti-TM4SF5 monoclonal antibody on human HCC cell migration
The tetraspanin superfamily, including TM4SF5, activates integrin-mediated signaling pathways that are pivotal for cell migration/invasion and tumor cell metastasis (10, 13, 14) .
Therefore, we evaluated the influence of the anti-TM4SF5 antibody on cell migration and invasion using human HCC cells of Huh-7 cell line expressing TM4SF5. As shown in Figs   2A and 2B, we found that the addition of the anti-TM4SF5 monoclonal antibody, but not PBS or IgG2a control, inhibited the migration of Huh-7 cells. In contrast, the antibody had little effect on the migration of SNU-739 cells that do not express TM4SF5. In addition, we performed a wound healing assay in vitro. As shown in Fig. 2C , the migration of Huh-7 cells into the wounded area was significantly reduced in the presence of the anti-TM4SF5 antibody but not PBS or IgG2a control. However, there was no difference in wound healing capacity in SNU-739 cells treated with IgG2a control or the anti-TM4SF5 antibody (Fig. 2C) . These results confirm that targeting TM4SF5 with this antibody reduces HCC cell motility in vitro.
Effect of the anti-TM4SF5 monoclonal antibody on E-cadherin expression and actin organization in HCC cells
E-cadherin is one of membrane adhesion molecules involved in cell-cell interaction, and reduced E-cadherin expression is associated with EMT and metastasis (24) . As the anti-TM4SF5 antibody reduces mobility of HCC cells, we then investigated expression of Ecadherin after treatment of Huh-7 cells and SNU-739 cells with anti-TM4SF5 antibody. First, we monitored E-cadherin expression by immunostaining and confocal microscopy. As shown in Figs 3A and 3B, E-cadherin expression was enhanced by the anti-TM4SF5 antibody in Huh-7 cells but not SNU-739 cells. There was no change in the cells treated with PBS or IgG2a control ( Fig. 3 and Supplementary Fig. S6 ). Accordingly, total E-cadherin protein expression increased following treatment of Huh-7 cells with the anti-TM4SF5 antibody, as determined by western blotting (Fig. 3C ). There was no change in expression of E-cadherin in SNU-739 cells after antibody treatment.
Next, we monitored actin organization in Huh-7 cells and SNU-739 cells after treatment with PBS, IgG2a control, or anti-TM4SF5 antibody using Phalloidin staining as well as paxillin staining. PBS and IgG2a control-treated Huh-7 cells displayed aberrant actin bundling, but treatment with the anti-TM4SF5 antibody resulted in the formation of well defined stress fibers ( Supplementary Fig. S7A ). In contrast, the well-defined stress fibers in SNU-739 cells supporting polygonal morphology were unaffected by treatment ( Supplementary Fig. S7A ). Staining of the focal adhesion molecule paxillin also revealed that the number of focal adhesion sites increased specifically in Huh-7 cells after treatment with anti-TM4SF5 antibody (Supplementary Fig. S7B ). Taken together, these results indicate that the anti-TM4SF5 monoclonal antibody modulates actin polymerization in TM4SF5 expressing cells. 
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The cyclin-dependent kinase inhibitor p27 kip1 negatively regulates cell proliferation through inhibition of G1/S cell cycle progression (25) . When we treated the TM4SF5-expressing Huh-7 cells with anti-TM4SF5 antibody, we found that growth of Huh-7 cells were suppressed (18) . Furthermore, previous study showed that p27 kip1 is localized in the cytosol of HCC cells overexpressing TM4SF5 (26) . Therefore, we examined expression and localization of p27 kip1 in Huh-7 and SNU-739 cells. Immunostaining and confocal microscopy revealed that p27 kip1 expression was not clearly detected in the nucleus of Huh-7 cells prior to treatment with the anti-TM4SF5 antibody. However, following treatment with the anti-TM4SF5 antibody, p27 kip1 staining was clearly observed in the nucleus (Fig. 3D ). In contrast, p27 kip1 localization did not change after treatment with the anti-TM4SF5 antibody in SNU-739 cells (Fig. 3E) . Western blotting showed no prominent change in the total levels of p27 kip1 protein expression in either cell line (Fig. 3F) . Therefore, treatment with the anti-TM4SF5 antibody induces the translocation of p27 kip1 from the cytosol to the nucleus and the nuclear p27 kip1 may suppress cell growth in Huh-7 cells.
RhoA is a small G protein involved in contact inhibition and regulates the actin cytoskeleton in the formation of stress fibers (27) . Furthermore, RhoA has been reported to be negatively regulated by p27 kip1 via a protein-protein interaction (28) (29) (30) . Therefore, translocation of p27 kip1 into the nucleus after treatment with anti-TM4SF5 antibody may reduce its interaction with RhoA and may enhance RhoA activity. As expected, the interaction between p27 kip1 and RhoA decreased and RhoA activity increased following treatment of Huh-7 cells with the anti-TM4SF5 antibody ( Supplementary Figs. S7C and S7D ). Treatment of Huh-7 cells with normal IgG had no effect. There was no effect in SNU-739 cells after (Fig. 5A-C) . However, antibody treatment did not affect the body weight of the mice during this experiment suggesting that the antibody has no prominent side effects (Fig. 5D ). The expression of TM4SF5 in HCC xenograft tumor tissue was confirmed by immunohistochemistry using the anti-TM4SF5 antibody (Fig. 5E ).
Together, these experiments suggest that the anti-TM4SF5 monoclonal antibody can attenuate tumor grown in mouse xenograft models of HCC. The anti-hTM4SF5 antibody did not affect the body weight of mice during the experiment, suggesting that the antibody has no prominent side effects (Fig. 6D) . Together, these experiments suggest that the anti-TM4SF5 monoclonal antibody can inhibit tumor growth in mouse syngeneic transplanted tumor models of HCC. 
Discussion
In this study, we confirmed that the TM4SF5 protein is over-expressed in human HCC, colon, and pancreatic cancer tissues using a high affinity monoclonal antibody against TM4SF5. Interestingly, TM4SF5 expression was detected in all of the HCC tissue samples we examined, at various expression levels (Table 1) . Therefore, we focused on HCC in this study; however, further investigation of TM4SF5 expression and function in colon and pancreatic cancer is warranted. In previous studies, we found that treatment with the anti-TM4SF5 monoclonal antibody inhibited the growth of human and mouse HCC cells and accordingly decreased the proportion of cells in S-phase (18) . Here, we further investigated in vitro and in vivo effects of anti-TM4SF5 antibody and the molecular mechanisms underlying the functional effects.
Treatment of Huh-7 cells with the anti-TM4SF5 monoclonal antibody significantly inhibited cell motility in vitro, as determined by migration, invasion, and wound healing assays (Fig. 2) . Furthermore, the expression of E-cadherin, stress fiber formation, and focal adhesion in Huh-7 cells was enhanced in response to the anti-TM4SF5 monoclonal antibody (Fig. 3) . Taken together, we can conclude that anti-TM4SF5 antibody provoke multiple in vitro anti-cancer effects including reduced cell growth, reduced motility, and enhanced adhesion.
E-cadherin, a member of calcium-dependent adhesion molecules mainly expressed in epithelial cells, is known to be downregulated in the situation of EMT and metastasis (24) . 
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adhesion molecules, cytokine receptors, and integrins (8, 9) . Therefore, the anti-TM4SF5 monoclonal antibody may also contribute to the interaction of TM4SF5 with adhesion molecules, such as E-cadherin, by stabilizing the cell-cell contacts, as has previously been suggested for antibody-based immunotherapeutics targeting another tetraspanin, CD151 (11) .
Fine regulation of RhoA activity is tightly associated with motility, and CDK inhibitors, such as p27 kip1 , p21 WAF1 , and p57, are known to modulate motility through interruption of the RhoA/ROCK signaling pathway (28) (29) (30) . Treatment of Huh-7 cells with the anti-TM4SF5 monoclonal antibody induced the translocation of p27 kip1 from the cytosol into the nucleus (Fig. 3) . p27 kip1 can play a role as a G1 check point in the nucleus, which might contribute to the decrease in the S-phase population and the reduced tumor cell growth observed in response to the anti-TM4SF5 antibody (18) . Furthermore, translocation of p27 kip1 was accompanied by the reduced association of p27 kip1 and RhoA and enhanced RhoA activity (Fig. 4) , and it significantly suppressed tumor growth (Fig. 5 and Fig. 6 ). Therefore, our results demonstrate that this anti-TM4SF5 monoclonal antibody has therapeutic effects in a mouse model of HCC and suggest that using this TM4SF5-specific monoclonal antibody could be investigated as a therapeutic strategy for HCC in humans.
The anti-tumor activity of the anti-TM4SF5 monoclonal antibody in vivo can be partially explained by the direct tumor suppressing activity of this antibody revealed in vitro. In addition, the antibody-dependent cell-mediated cytotoxicity (ADCC) and complementdependent cytotoxicity (CDC) could play a role in vivo. ADCC involving antibodies and Fc receptors of cytotxcic cells such as NK cells, macrophages, and neurophiles is known to be an important mechanism involved in the anti-tumor function of therapeutic antibodies such as trastuzumab and tituximab (31). Antigen-specific antibodies can trigger CDC through the classical complement pathway (32). Therefore, the immunological function of anti-TM4SF5 monoclonal antibody in mice has to be examined. Induction of the antibody-mediated effector function is highly dependent on the isotype of the antibody, and most of the potent therapeutic antibodies on the market are IgG1 (33) probably because IgG1 is the most abundant IgG subclass in human serum and has high affinity for Fc receptors on pahgocytic cells in human (34). The anti-TM4SF5 monoclonal antibody used in this study is the isotype IgG2a. As IgG2a has extremely low affinity for Fc Receptors on phagocytic cells in human (34), further consideration of the isotype may be required for the future application of this antibody in humans. Considering that TM4SF5 is involved in EMT and metastasis (13) (14) (15) (16) , and that the treatment of TM4SF5-expressing cells with the anti-TM4SF5 monoclonal antibody reduced motility and enhanced expression of E-cadherin, the anti-TM4SF5 monoclonal antibody may have anti-metastatic activity and therefore may be able to 
